Pandemic influenza immunization in primary antiphospholipid syndrome (PAPS): a trigger to thrombosis and autoantibody production?

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMEDEIROS, D. Martins de
dc.contributor.authorSILVA, C. A.
dc.contributor.authorBUENO, C.
dc.contributor.authorRIBEIRO, A. C. Medeiros
dc.contributor.authorVIANA, V. dos Santos T.
dc.contributor.authorCARVALHO, J. Freire
dc.contributor.authorBONFA, E.
dc.date.accessioned2015-04-22T22:15:14Z
dc.date.available2015-04-22T22:15:14Z
dc.date.issued2014
dc.description.abstractObjective The objective of this report is to conduct short- and long-term evaluation of a large panel of antiphospholipid (aPL) autoantibodies following pandemic influenza A/H1N1 non-adjuvant vaccine in primary antiphospholipid syndrome (PAPS) patients and healthy controls. Methods Forty-five PAPS and 33 healthy controls were immunized with H1N1 vaccine. They were prospectively assessed at pre-vaccination, and three weeks and six months after vaccination. aPL autoantibodies were determined by an enzyme-linked immunosorbent assay (ELISA) and included IgG/IgM: anticardiolipin (aCL), anti-beta2glycoprotein I (anti-2GPI); anti-annexin V, anti-phosphatidyl serine and anti-prothrombin antibodies. Anti-Sm was determined by ELISA and anti-double-stranded DNA (anti-dsDNA) by indirect immunofluorescence. Arterial and venous thrombosis were also clinically assessed. Results Pre-vaccination frequency of at least one aPL antibody was significantly higher in PAPS patients versus controls (58% vs. 24%, p=0.0052). The overall frequencies of aPL antibody at pre-vaccination, and three weeks and six months after immunization remained unchanged in patients (p=0.89) and controls (p=0.83). The frequency of each antibody specificity for patients and controls remained stable in the three evaluated periods (p>0.05). At three weeks, two PAPS patients developed a new but transient aPL antibody (aCL IgG and IgM), whereas at six months new aPL antibodies were observed in six PAPS patients and none had high titer. Anti-Sm and anti-dsDNA autoantibodies were uniformly negative and no new arterial or venous thrombosis were observed throughout the study. Conclusions This is the first study to demonstrate that pandemic influenza vaccine in PAPS patients does not trigger short- and long-term thrombosis or a significant production of aPL-related antibodies (ClinicalTrials.gov, #NCT01151644).
dc.description.indexMEDLINE
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo [FAPESP 2009/51897-5, 2010/10749-0]
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico [CNPQ 300665/2009-1, 302724/2011-7, 301411/2009-3]
dc.description.sponsorshipFederico Foundation
dc.description.sponsorshipButantan Foundation
dc.description.sponsorshipNucleo de Apoio a Pesquisa ""Saude da Crianca e do Adolescente'' da USP (NAP-CriAd)
dc.identifier.citationLUPUS, v.23, n.13, p.1412-1416, 2014
dc.identifier.doi10.1177/0961203314540351
dc.identifier.eissn1477-0962
dc.identifier.issn0961-2033
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/9042
dc.language.isoeng
dc.publisherSAGE PUBLICATIONS LTD
dc.relation.ispartofLupus
dc.rightsrestrictedAccess
dc.rights.holderCopyright SAGE PUBLICATIONS LTD
dc.subjectVaccine
dc.subjectantiphospholipid antibodies
dc.subjectpandemic influenza A
dc.subjectH1N1
dc.subjectantiphospholipid syndrome
dc.subject.othersystemic-lupus-erythematosus
dc.subject.otherrheumatic-disease
dc.subject.othervaccination
dc.subject.otherantibodies
dc.subject.wosRheumatology
dc.titlePandemic influenza immunization in primary antiphospholipid syndrome (PAPS): a trigger to thrombosis and autoantibody production?
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalCARVALHO, J. Freire:Univ Fed Bahia, Div Rheumatol, BR-41170290 Salvador, BA, Brazil
hcfmusp.citation.scopus10
hcfmusp.contributor.author-fmusphcDANIELLE MARTINS DE MEDEIROS HISANO
hcfmusp.contributor.author-fmusphcCLOVIS ARTUR ALMEIDA DA SILVA
hcfmusp.contributor.author-fmusphcCLEONICE BUENO
hcfmusp.contributor.author-fmusphcANA CRISTINA DE MEDEIROS RIBEIRO
hcfmusp.contributor.author-fmusphcVILMA DOS SANTOS TRINDADE VIANA
hcfmusp.contributor.author-fmusphcELOISA SILVA DUTRA DE OLIVEIRA BONFA
hcfmusp.description.beginpage1412
hcfmusp.description.endpage1416
hcfmusp.description.issue13
hcfmusp.description.volume23
hcfmusp.origemWOS
hcfmusp.origem.pubmed24961747
hcfmusp.origem.scopus2-s2.0-84909608147
hcfmusp.origem.wosWOS:000344064900009
hcfmusp.publisher.cityLONDON
hcfmusp.publisher.countryENGLAND
hcfmusp.relation.referenceAbu-Shakra M, 2002, CLIN RHEUMATOL, V21, P369, DOI 10.1007/s100670200099
hcfmusp.relation.referenceAgmon-Levin N, 2009, ISR MED ASSOC J, V11, P183
hcfmusp.relation.referenceCrowe SR, 2011, ARTHRITIS RHEUM-US, V63, P2396, DOI 10.1002/art.30388
hcfmusp.relation.referenceCruz-Tapias P, 2012, CURR OPIN RHEUMATOL, V24, P389, DOI 10.1097/BOR.0b013e32835448b8
hcfmusp.relation.referenceLu CC, 2011, VACCINE, V29, P444, DOI 10.1016/j.vaccine.2010.10.081
hcfmusp.relation.referenceMEYER A, 2012, ISR MED ASSOC J, V12, P638
hcfmusp.relation.referencePerdan-Pirkmajer K, 2012, LUPUS, V21, P175, DOI 10.1177/0961203311429817
hcfmusp.relation.referencePorobic JM, 2005, CLIN EXP IMMUNOL, V142, P377, DOI 10.1111/j.1365-2249.2005.02923.x
hcfmusp.relation.referenceSaad CGS, 2011, ANN RHEUM DIS, V70, P1068, DOI 10.1136/ard.2011.150250
hcfmusp.relation.referenceShoenfeld Y, 2011, J AUTOIMMUN, V36, P4, DOI 10.1016/j.jaut.2010.07.003
hcfmusp.relation.referenceSilva CA, 2013, NAT REV RHEUMATOL, V9, P532, DOI 10.1038/nrrheum.2013.95
hcfmusp.relation.referenceSilva CAA, 2010, REV BRAS REUMATOL, V50, P351, DOI 10.1590/S0482-50042010000400002
hcfmusp.relation.referenceUrowitz MB, 2011, ARTHRIT CARE RES, V63, P1517, DOI 10.1002/acr.20599
hcfmusp.relation.referencevan Assen S, 2011, ANN RHEUM DIS, V70, P414, DOI 10.1136/ard.2010.137216
hcfmusp.relation.referenceVista ES, 2012, LUPUS, V21, P168, DOI 10.1177/0961203311429554
hcfmusp.relation.referenceWilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication94e76b74-be83-48be-8bca-2bad0e69379d
relation.isAuthorOfPublication6c3c5459-9dbb-4a5c-98b1-d7b76943b87d
relation.isAuthorOfPublication9f03c248-d76b-40d9-b126-ed23014c4719
relation.isAuthorOfPublication4df1830e-3116-447c-9f1a-363406d1ad11
relation.isAuthorOfPublication798a3a64-2f34-43cc-8607-d79c1f218edd
relation.isAuthorOfPublication708e64de-56af-4523-b920-b237f71535b2
relation.isAuthorOfPublication.latestForDiscovery708e64de-56af-4523-b920-b237f71535b2
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_MEDEIROS_Pandemic_influenza_immunization_in_primary_antiphospholipid_syndrome_PAPS_2014.PDF
Tamanho:
84.26 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPE
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - LIM/36
Carregar mais